|Product:||Bismuth nanoparticled for small animal liver and spleen micro-CT Imaging. The product enables low dose high definition imaging of the liver and spleen system. Following administration, the contrast agent is taken up instantaneously by reticulo-endothelial system (first pass uptake) in liver. The dose required to achieve high-resolution micro-CT imaging is as low as 30 μL (IV admin) for a conventional micro-CT system.|
|Composition:||Bismuth (III) oxide core with starch coating|
|Application:||Liver and spleen imaging. Protein conjugation for targeted imaging.|
|Disciplines:||Oncology, hepatic disease research|
|Particle size:||250 nm|
|Product information:||Certificate of Analysis|
Low Dose High Definition Liver & Spleen Imaging
Representative images (axial, coronal, saggital) acquired 15 minutes post injection following mouse tail vein injection with 30 uL of Mvivo BIS (Courtesy of M. Waleed Gaber, Texas Children’s Hospital).
micro-CT Liver Imaging
- Chase Romere, Clemens Duerrschmid, Juan Bournat, Petra Constable, Mahim Jain, Fan Xia, Pradip K. Saha, Maria Del Solar, Bokai Zhu, Brian York, Poonam Sarkar, David A. Rendon, M. Waleed Gaber, Scott A. LeMaire, Joseph S. Coselli, Dianna M. Milewicz, V. Reid Sutton, Nancy F. Butte, David D. Moore, Atul R. Chopra. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 April 21; 165(3): 566–579.